AZ's Brilinta Takes Next Step, Gains FDA Approval For Extended Use
This article was originally published in Scrip
Executive Summary
The US FDA has approved AstraZeneca PLC's oral antiplatelet treatment, Brilinta (ticagrelor), in a new indication, allowing the product to be used as a longer term therapy for patients with acute coronary syndrome (ACS).